Header Logo

Connection

Gary Raskob to Pyrazoles

Back to Details
This is a "connection" page, showing publications Gary Raskob has written about Pyrazoles.
Gary Raskob
Connection Strength
2.220
Pyrazoles
  1. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16.
    View in: PubMed
    Score: 0.499
  2. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64.
    View in: PubMed
    Score: 0.382
  3. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):130-139.
    View in: PubMed
    Score: 0.166
  4. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
    View in: PubMed
    Score: 0.163
  5. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
    View in: PubMed
    Score: 0.155
  6. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164.
    View in: PubMed
    Score: 0.131
  7. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91.
    View in: PubMed
    Score: 0.124
  8. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
    View in: PubMed
    Score: 0.105
  9. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51.
    View in: PubMed
    Score: 0.103
  10. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708.
    View in: PubMed
    Score: 0.101
  11. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98.
    View in: PubMed
    Score: 0.088
  12. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15.
    View in: PubMed
    Score: 0.084
  13. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604.
    View in: PubMed
    Score: 0.080
  14. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.